Trump administration delays rule restricting imported prescription drugs from Canada
The Trump administration has delayed a federal rule targeting low-value foreign shipments by 90 days after criticism from patient groups and lawmakers.
Delay targets de minimis exemption
The new regulation was originally scheduled to take effect on October 22. This change affects the de minimis exemption that previously allowed shipments under $800 to pass through customs easily. The administration aims to stop illegal goods like opioids entering via these low-value foreign packages.
Critics urge rethink of approach
Patient advocacy groups and dozens of congressional lawmakers asked the government to reconsider its strategy. They argue the rule could drastically reduce access to medicines from licensed international pharmacies. The delay gives time for further discussion on balancing drug access with security concerns.
Tracking data remains a goal
Officials state that shippers generally do not pay tariffs or submit tracking data for these specific shipments. The rule seeks to crack down on untracked goods while maintaining oversight of legitimate trade flows. This pause allows the administration to refine how it monitors cross-border medicine imports.
Reported by one outlet
Only one outlet has published this. Nothing here has been checked against a second report, so read it as that outlet's account and follow the link below for the original.
Reported by
1 independent outlet. Headline as published. Links open the original report.